Symbiance Pharma Solutions Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.40 Cr
as on 02-07-2024
- Revenue 88.28%
(FY 2023)
- Profit 20.32%
(FY 2023)
- Ebitda 48.41%
(FY 2023)
- Net Worth 241.91%
(FY 2023)
- Total Assets 51.41%
(FY 2023)
About Symbiance Pharma Solutions
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.40 Cr.
Shree Thamizadiyan and Lakshmanan Vasanthakumar serve as directors at the Company.
- CIN/LLPIN
U72900TN2016PTC112455
- Company No.
112455
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Sep 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Symbiance Pharma Solutions?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lakshmanan Vasanthakumar  | Director | 27-Jan-2022 | Current |
| Shree Thamizadiyan | Director | 06-Apr-2023 | Current |
Financial Performance of Symbiance Pharma Solutions.
Symbiance Pharma Solutions Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 88.28% increase. The company also saw a substantial improvement in profitability, with a 20.32% increase in profit. The company's net worth Soared by an impressive increase of 241.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiance Pharma Solutions?
In 2023, Symbiance Pharma Solutions had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 12 Jan 2023 | ₹5.00 Cr | Open |
Hdfc Bank Limited Creation Date: 25 Jan 2022 | ₹4.00 M | Open |
How Many Employees Work at Symbiance Pharma Solutions?
Symbiance Pharma Solutions has a workforce of 249 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiance Pharma Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiance Pharma Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
